Precigen is trading 10.25% down at $7.67, with no clear company-specific catalyst identified. - Its press-release page lists the September 21 FDA platform designation as its latest announcement, with no October 5 release listed. - The broader market is higher, so the supplied market context does not explain the decline. The FDA designation is prior news, not a confirmed cause.